An open-label, randomized, single-dose, 4 period crossover relative bioavailability study comparing APC-5000 (fluticasone propionate and salmeterol xinafoate) and Advair Diskus

Trial Profile

An open-label, randomized, single-dose, 4 period crossover relative bioavailability study comparing APC-5000 (fluticasone propionate and salmeterol xinafoate) and Advair Diskus

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2015

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 05 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top